Desvenlafaxine Succinate | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Desvenlafaxine Succinate
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Desvenlafaxine Succinate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

50 API Suppliers, 28 USDMF, 14 EU WC, 11 KDMF, 15 NDC API, 31 Listed Suppliers, $ API Reference Price

50 API Suppliers
28 USDMF
14 EU WC
11 KDMF
15 NDC API
31 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

119 FDF Dossiers, 34 FDA Orange Book, 6 Europe, 20 Canada, 32 Australia, 10 South Africa, 17 Listed Dossiers

119 FDF Dossiers
34 FDA Orange Book
6 Europe
20 Canada
32 Australia
10 South Africa
17 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - EQ 100MG BASE, TABLET, EXTENDED RELEASE;ORAL - EQ 25MG BASE, TABLET, EXTENDED RELEASE;ORAL - EQ 50MG BASE

TABLET, EXTENDED RELEASE;ORAL - EQ 100MG BASE
TABLET, EXTENDED RELEASE;ORAL - EQ 25MG BASE
TABLET, EXTENDED RELEASE;ORAL - EQ 50MG BASE

RELATED EXCIPIENT COMPANIES

1 Minakem, 2 SPI Pharma, 2 Seqens, 4 DKSH, 1 Faran Shimi Pharmaceutical, 5 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 3 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 Pramukh Pharmachem, 1 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 5 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 BASF, 1 Clariant, 10 Corel Pharma Chem, 2 DFE Pharma, 2 Finar, 7 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 17 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 8 Microlex e.U, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 1 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 9 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 9 Sigachi Industries, 2 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 2 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

51 Coating Systems & Additives, 28 Fillers, Diluents & Binders, 27 Controlled & Modified Release, 22 Lubricants & Glidants, 19 Thickeners and Stabilizers, 15 Topical, 13 Film Formers & Plasticizers, 9 Disintegrants & Superdisintegrants, 9 Direct Compression, 8 Co-Processed Excipients, 8 Granulation, 8 Solubilizers, 6 API Stability Enhancers, 5 Empty Capsules, 5 Coloring Agents, 5 Emulsifying Agents, 5 Chewable & Orodispersible Aids, 5 Parenteral, 4 Vegetarian Capsules, 4 Taste Masking, 2 Rheology Modifiers

51 Coating Systems & Additives
28 Fillers, Diluents & Binders
27 Controlled & Modified Release
22 Lubricants & Glidants
19 Thickeners and Stabilizers
15 Topical
13 Film Formers & Plasticizers
9 Disintegrants & Superdisintegrants
9 Direct Compression
8 Co-Processed Excipients
8 Granulation
8 Solubilizers
6 API Stability Enhancers
5 Empty Capsules
5 Coloring Agents
5 Emulsifying Agents
5 Chewable & Orodispersible Aids
5 Parenteral
4 Vegetarian Capsules
4 Taste Masking
2 Rheology Modifiers

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 16 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
16 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 9 Finished Drug Prices, 6 Annual Reports

1 US Medicaid Prescriptions
9 Finished Drug Prices
6 Annual Reports

MARKET PLACE

10 APIs, 1 FDF Dossiers

10 APIs
1 FDF Dossiers

PATENTS & EXCLUSIVITIES

3 US Patents, 2 Health Canada Patents

3 US Patents
2 Health Canada Patents

REF. STANDARDS & IMPURITIES

4 Others

4 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 725 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2Pfizer Canada ULC

filter Patent Reset all filters

2 All

01 22436668

filter Product Reset all filters

2 All

01 2Desvenlafaxine Succinate

filter Dosage Reset all filters

2 All

01 2Tablet, Extended Release

filter Exp Date Reset all filters

2 All

01 22022-02-11

Product Main Page

01

Pfizer Canada ULC

Desvenlafaxine Succinate

PharmScience R&D

Not Confirmed

Pfizer Canada ULC

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2022-02-11

Date Granted : 2009-05-26

Desvenlafaxine Succinate

Brand Name : PRISTIQ

Patent Number : 2436668

Filing Date : 2002-02-11

Strength per Unit : 50mg

Dosage Form : Tablet, Extended Release

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2022-02-11

Date Granted : 2009-05-26

Portfolio PDF

Product Web Link

Digital Content

02

Pfizer Canada ULC

Desvenlafaxine Succinate

PharmScience R&D

Not Confirmed

Pfizer Canada ULC

PharmScience R&D

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2022-02-11

Date Granted : 2009-05-26

Desvenlafaxine Succinate

Brand Name : PRISTIQ

Patent Number : 2436668

Filing Date : 2002-02-11

Strength per Unit : 100mg

Dosage Form : Tablet, Extended Release

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2022-02-11

Date Granted : 2009-05-26

Portfolio PDF

Product Web Link

Digital Content

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!